|
|
预防性腹腔热灌注化疗治疗进展期结直肠癌的预后分析：一项倾向评分匹配分析
|
Abstract:
目的：探究对进展期结直肠癌(Colorectal Cancer, CRC)患者术后预防性腹腔热灌注化疗(Hyperthermic Intraperitoneal Chemotherapy)的安全性、有效性以及对生存情况的影响。方法：回顾性分析2018至2020年于青岛大学附属医院接受根治性手术进展期结直肠癌患者的临床资料，其中HIPEC组135例，对照组165例，经过1:1比例进行倾向评分匹配(propensity score matching, PSM)后将252例患者按是否接受HIPEC干预分为两组：HIPEC组(n = 126)与对照组(n = 126)。对入组患者进行围术期安全性分析及术后长期随访。结果：HIPEC组总生存期为(36.25 ± 0.780)个月；对照组为(32.97 ± 1.065)个月，两组3年总生存率(83.3% vs. 73.8%)差异具有统计学意义(P = 0.044)。HIPEC组3年无复发生存率为85.7%，对照组为75.4%，组间差异具有统计学意义(P = 0.027)。两组术后严重并发症方面无明显统计学差异(P > 0.05)。血管侵犯、pT分期以及预防性HIPEC治疗是影响患者术后DFS的独立危险因素：血管侵犯(HR = 1.893, 95% CI 1.080~3.318, P = 0.026)与pT分期(HR = 2.439, 95% CI 1.385~4.295, P = 0.002)与复发风险显著相关。而预防性HIPEC可降低术后复发风险(HR = 0.465, 95% CI 0.258~0.835, P = 0.010)。结论：预防性腹腔热灌注化疗(HIPEC)可以有效降低发生腹膜转移的风险并使进展期结直肠癌患者的生存获益，同时预防性HIPEC并未显著增加术后并发症的发生率，这说明预防性HIPEC是一种安全、可行的治疗手段，而血管侵犯和pT4分期是肿瘤复发的重要危险因素。
Objective: To investigate the safety, efficacy, and impact on survival outcomes of prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with advanced colorectal cancer (CRC) after surgery. Methods: We retrospectively analyzed clinical data from advanced CRC patients who underwent radical surgery at the Affiliated Hospital of Qingdao University from 2018 to 2020, including 135 cases in the HIPEC group and 165 cases in the control group. After 1:1 propensity score matching (PSM), 252 patients were divided into two groups based on HIPEC intervention: the HIPEC group (n = 126) and the control group (n = 126). Perioperative safety analysis and long-term postoperative follow-up were conducted. Results: The overall survival (OS) was (36.25 ± 0.780) months in the HIPEC group versus (32.97 ± 1.065) months in the control group. The 3-year OS rates (83.3% vs. 73.8%) showed a statistically significant difference (P = 0.044). The 3-year recurrence-free survival rate was 85.7% in the HIPEC group and 75.4% in the control group, with a statistically significant difference between the groups (P = 0.027). No significant difference in severe postoperative complications was observed (P > 0.05). Vascular invasion, pT stage, and prophylactic HIPEC were independent risk factors for postoperative DFS: vascular invasion (HR = 1.893, 95% CI 1.080~3.318, P = 0.026) and pT stage (HR = 2.439, 95% CI 1.385~4.295, P = 0.002) significantly correlated with recurrence risk. Prophylactic HIPEC reduced recurrence risk (HR = 0.465, 95% CI 0.258~0.835, P = 0.010).
| [1] | Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. https://doi.org/10.3322/caac.21763 |
| [2] | (2023) Chinese Protocol of Diagnosis and Treatment of Colorectal Cancer (2023 Edition). Chinese Journal of Surgery, 61, 617-644. |
| [3] | Jayne, D.G., Fook, S., Loi, C. and Seow-Choen, F. (2002) Peritoneal Carcinomatosis from Colorectal Cancer. British Journal of Surgery, 89, 1545-1550. https://doi.org/10.1046/j.1365-2168.2002.02274.x |
| [4] | Kerscher, A.G., Chua, T.C., Gasser, M., Maeder, U., Kunzmann, V., Isbert, C., et al. (2013) Impact of Peritoneal Carcinomatosis in the Disease History of Colorectal Cancer Management: A Longitudinal Experience of 2406 Patients over Two Decades. British Journal of Cancer, 108, 1432-1439. https://doi.org/10.1038/bjc.2013.82 |
| [5] | Franko, J., Shi, Q., Meyers, J.P., Maughan, T.S., Adams, R.A., Seymour, M.T., et al. (2016) Prognosis of Patients with Peritoneal Metastatic Colorectal Cancer Given Systemic Therapy: An Analysis of Individual Patient Data from Prospective Randomised Trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) Database. The Lancet Oncology, 17, 1709-1719. https://doi.org/10.1016/s1470-2045(16)30500-9 |
| [6] | Elias, D., Honoré, C., Dumont, F., Ducreux, M., Boige, V., Malka, D., et al. (2011) Results of Systematic Second-Look Surgery Plus HIPEC in Asymptomatic Patients Presenting a High Risk of Developing Colorectal Peritoneal Carcinomatosis. Annals of Surgery, 254, 289-293. https://doi.org/10.1097/sla.0b013e31822638f6 |
| [7] | Elias, D., Lefevre, J.H., Chevalier, J., Brouquet, A., Marchal, F., Classe, J., et al. (2009) Complete Cytoreductive Surgery plus Intraperitoneal Chemohyperthermia with Oxaliplatin for Peritoneal Carcinomatosis of Colorectal Origin. Journal of Clinical Oncology, 27, 681-685. https://doi.org/10.1200/jco.2008.19.7160 |
| [8] | Quénet, F., Elias, D., Roca, L., Goéré, D., Ghouti, L., Pocard, M., et al. (2021) Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy versus Cytoreductive Surgery Alone for Colorectal Peritoneal Metastases (PRODIGE 7): A Multicentre, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 256-266. https://doi.org/10.1016/s1470-2045(20)30599-4 |
| [9] | Verwaal, V.J., Bruin, S., Boot, H., van Slooten, G. and van Tinteren, H. (2008) 8-Year Follow-Up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer. Annals of Surgical Oncology, 15, 2426-2432. https://doi.org/10.1245/s10434-008-9966-2 |
| [10] | Larentzakis, A., O'Dwyer, S.T., Becker, J., Shuweihdi, F., Aziz, O., Selvasekar, C.R., et al. (2019) Referral Pathways and Outcome of Patients with Colorectal Peritoneal Metastasis (CRPM). European Journal of Surgical Oncology, 45, 2310-2315. https://doi.org/10.1016/j.ejso.2019.07.008 |
| [11] | Klaver, C.E.L., Wisselink, D.D., Punt, C.J.A., Snaebjornsson, P., Crezee, J., Aalbers, A.G.J., et al. (2019) Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients with Locally Advanced Colon Cancer (COLOPEC): A Multicentre, Open-Label, Randomised Trial. The Lancet Gastroenterology & Hepatology, 4, 761-770. https://doi.org/10.1016/s2468-1253(19)30239-0 |
| [12] | Goéré, D., Glehen, O., Quenet, F., Guilloit, J., Bereder, J., Lorimier, G., et al. (2020) Second-Look Surgery plus Hyperthermic Intraperitoneal Chemotherapy versus Surveillance in Patients at High Risk of Developing Colorectal Peritoneal Metastases (PROPHYLOCHIP-PRODIGE 15): A Randomised, Phase 3 Study. The Lancet Oncology, 21, 1147-1154. https://doi.org/10.1016/s1470-2045(20)30322-3 |
| [13] | Goéré, D., Souadka, A., Faron, M., Cloutier, A.S., Viana, B., Honoré, C., et al. (2015) Extent of Colorectal Peritoneal Carcinomatosis: Attempt to Define a Threshold above Which HIPEC Does Not Offer Survival Benefit: A Comparative Study. Annals of Surgical Oncology, 22, 2958-2964. https://doi.org/10.1245/s10434-015-4387-5 |
| [14] | Elias, D., Gilly, F., Boutitie, F., Quenet, F., Bereder, J., Mansvelt, B., et al. (2010) Peritoneal Colorectal Carcinomatosis Treated with Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients from a Multicentric French Study. Journal of Clinical Oncology, 28, 63-68. https://doi.org/10.1200/jco.2009.23.9285 |
| [15] | Kuijpers, A.M.J., Mirck, B., Aalbers, A.G.J., Nienhuijs, S.W., de Hingh, I.H.J.T., Wiezer, M.J., et al. (2013) Cytoreduction and HIPEC in the Netherlands: Nationwide Long-Term Outcome Following the Dutch Protocol. Annals of Surgical Oncology, 20, 4224-4230. https://doi.org/10.1245/s10434-013-3145-9 |
| [16] | Arjona-Sánchez, A. (2023) Efficacy, Safety, and Analysis Issues in a Study of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer—Reply. JAMA Surgery, 158, 1358. https://doi.org/10.1001/jamasurg.2023.3486 |
| [17] | Marin, D., Catalano, C., Baski, M., Di Martino, M., Geiger, D., Di Giorgio, A., et al. (2009) 64-Section Multi-Detector Row CT in the Preoperative Diagnosis of Peritoneal Carcinomatosis: Correlation with Histopathological Findings. Abdominal Imaging, 35, 694-700. https://doi.org/10.1007/s00261-008-9464-9 |
| [18] | Amin, M.B., Greene, F.L., Edge, S.B., Compton, C.C., Gershenwald, J.E., Brookland, R.K., et al. (2017) The Eighth Edition AJCC Cancer Staging Manual: Continuing to Build a Bridge from a Population‐Based to a More “Personalized” Approach to Cancer Staging. CA: A Cancer Journal for Clinicians, 67, 93-99. https://doi.org/10.3322/caac.21388 |
| [19] | Benson, A.B., Venook, A.P., Adam, M., et al. (2024) Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 22, e240029. |
| [20] | Benson, A.B., Venook, A.P., Al-Hawary, M.M., Azad, N., Chen, Y., Ciombor, K.K., et al. (2022) Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 20, 1139-1167. https://doi.org/10.6004/jnccn.2022.0051 |
| [21] | Glehen, O., Gilly, F.N., Boutitie, F., Bereder, J.M., Quenet, F., Sideris, L., et al. (2010) Toward Curative Treatment of Peritoneal Carcinomatosis from Nonovarian Origin by Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy: A Multi-Institutional Study of 1,290 Patients. Cancer, 116, 5608-5618. https://doi.org/10.1002/cncr.25356 |
| [22] | Kwong, M.L.M., Sampah, M.E.S., Bello, B.L. and Sugarbaker, P.H. (2019) Port Site Metastases after Minimally Invasive Resection for Colorectal Cancer: A Retrospective Study of 13 Patients. Surgical Oncology, 29, 20-24. https://doi.org/10.1016/j.suronc.2019.02.008 |
| [23] | Nagata, H., Kawai, K., Oba, K., Nozawa, H., Yamauchi, S., Sugihara, K., et al. (2022) Laparoscopic Colectomy: A Risk Factor for Postoperative Peritoneal Metastasis. Clinical Colorectal Cancer, 21, e205-e212. https://doi.org/10.1016/j.clcc.2022.05.003 |
| [24] | Parascandola, S.A., Horsey, M.L., Hota, S., Sparks, A.D., Tampo, M.M.T., Kim, G., et al. (2020) Surgical Resection of T4 Colon Cancers: An NCDB Propensity Score-Matched Analysis of Open, Laparoscopic, and Robotic Approaches. Journal of Robotic Surgery, 15, 701-710. https://doi.org/10.1007/s11701-020-01166-4 |
| [25] | Petrucciani, N., Martínez-Pérez, A., Bianchi, G., Memeo, R., Brunetti, F. and de’Angelis, N. (2018) The Use of Laparoscopy for Locally Advanced Rectal Cancer. Minerva Surgery, 73, 77-92. https://doi.org/10.23736/s0026-4733.17.07568-x |
| [26] | Hompes, D., Tiek, J., Wolthuis, A., Fieuws, S., Penninckx, F., Van Cutsem, E., et al. (2012) HIPEC in T4a Colon Cancer: A Defendable Treatment to Improve Oncologic Outcome? Annals of Oncology, 23, 3123-3129. https://doi.org/10.1093/annonc/mds173 |
| [27] | Grothey, A., Sobrero, A.F., Shields, A.F., Yoshino, T., Paul, J., Taieb, J., et al. (2018) Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. New England Journal of Medicine, 378, 1177-1188. https://doi.org/10.1056/nejmoa1713709 |
| [28] | Sammartino, P., Sibio, S., Biacchi, D., Cardi, M., Mingazzini, P., Rosati, M.S., et al. (2014) Long-Term Results after Proactive Management for Locoregional Control in Patients with Colonic Cancer at High Risk of Peritoneal Metastases. International Journal of Colorectal Disease, 29, 1081-1089. https://doi.org/10.1007/s00384-014-1929-4 |
| [29] | Fan, B., Bu, Z., Zhang, J., Zong, X., Ji, X., Fu, T., et al. (2021) Phase II Trial of Prophylactic Hyperthermic Intraperitoneal Chemotherapy in Patients with Locally Advanced Gastric Cancer after Curative Surgery. BMC Cancer, 21, Article No. 216. https://doi.org/10.1186/s12885-021-07925-2 |
